Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide

Area of Science:

• Gastroenterology
• Pediatric Surgery
• Pharmacology

Background:

• Teduglutide, a glucagon-like peptide 2 (GLP-2) analogue, is FDA-approved for pediatric short bowel syndrome (SBS).
• GLP-2 analogues enhance intestinal adaptation and absorptive capacity, reducing parenteral nutrition needs.
• A theoretical risk of proliferative complications exists with GLP-2 analogue therapy.

Purpose of the Study:

• To report an unusual case of a pediatric patient treated with teduglutide.
• To highlight a potential complication associated with teduglutide therapy in a patient with a specific surgical history.

Main Methods:

• Case report of a pediatric patient with short bowel syndrome.
• Review of the patient's medical history, including a prior surgical procedure in infancy.
• Clinical observation during treatment with teduglutide.

Main Results:

• A decade-old, discontinuous retained segment of colon was identified in the patient.
• This retained segment became clinically significant following teduglutide treatment.
• The case illustrates a rare, potentially unforeseen consequence of teduglutide therapy.

Conclusions:

• Teduglutide therapy can be associated with unexpected clinical events in patients with complex surgical histories.
• Retained intestinal segments, even if long-standing, may react to GLP-2 analogue treatment.
• Further vigilance is warranted for potential proliferative complications in pediatric patients receiving teduglutide.